+

WO2011162989A2 - Modulation par le récepteur du glp-1 de la pharmacodépendance, des troubles neuropsychiatriques et du dysfonctionnement érectile - Google Patents

Modulation par le récepteur du glp-1 de la pharmacodépendance, des troubles neuropsychiatriques et du dysfonctionnement érectile Download PDF

Info

Publication number
WO2011162989A2
WO2011162989A2 PCT/US2011/040008 US2011040008W WO2011162989A2 WO 2011162989 A2 WO2011162989 A2 WO 2011162989A2 US 2011040008 W US2011040008 W US 2011040008W WO 2011162989 A2 WO2011162989 A2 WO 2011162989A2
Authority
WO
WIPO (PCT)
Prior art keywords
glp
subject
administered
administering
receptor
Prior art date
Application number
PCT/US2011/040008
Other languages
English (en)
Other versions
WO2011162989A3 (fr
Inventor
Aurelio Galli
Kevin Erreger
Kevin Niswender
Sabrina Robertson
Christine Saunders
Heiner Matthies
Adeola Davis
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of WO2011162989A2 publication Critical patent/WO2011162989A2/fr
Publication of WO2011162989A3 publication Critical patent/WO2011162989A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates generally to the fields of neurobiology and neurophysiology. More particularly, it concerns the use of glucagon-like peptide 1 (GLP-1) for modulating dopamine homeostasis and the activity of dopamine transporters in the context of addictive substance use and abuse and neuropsychiatric disorders.
  • GLP-1 glucagon-like peptide 1
  • the present invention relates generally to the fields of biology and pharmacology. More particularly, it concerns the use of GLP-1 receptor agonists, including GLP-1 and GLP-1 analogs, for treating erectile dysfunction.
  • GLP-1 receptor agonists including GLP-1 and GLP-1 analogs
  • Drug dependence is considered a multi-factorial health disorder that often follows the course of a relapsing and remitting chronic disease.
  • drug dependence is still not recognized as a health problem and many people suffering from it are stigmatized and have no access to treatment and rehabilitation.
  • the biopsychosocial model has recognized drug dependence as a multifaceted problem requiring the expertise of many disciplines.
  • a health sciences multidisciplinary approach can be applied to research, prevention and treatment.
  • Drug dependence and illicit drug use are associated with health problems, poverty, violence, criminal behavior, and social exclusion. Its total costs to society are difficult to estimate, but can certainly be measured in the hundreds of billions of dollars. In addition to the health care costs and other costs associated with the consequences of drug use; drug dependence involves also social costs in the form of loss of productivity and family income, violence, security problems, traffic and workplace accidents, and links with corruption. These result in overwhelming economic costs and an unacceptable waste of human resources.
  • IDU injecting drug use
  • IDU injecting drug use
  • Non-injecting drug use is also linked to HIV transmission by increasing high risk sexual behaviors.
  • Data on the size of the IDU population from 130 countries indicates that there are close to 10 million IDUs worldwide.
  • Up to 10% of global HIV infections are due to unsafe injecting drug use, and if Sub-Saharan Africa is excluded, up to 30% of global HIV infections are due to unsafe injecting drug use.
  • the sharing of contaminated injection equipment is a major route of HIV transmission in many regions, including Eastern Europe, Central, South and South East Asia and some countries in Latin America.
  • a number of forms of treatment for substance dependence exist, including pychotherapy and behavioral therapy, as well as replacement or antagonist drugs such as methadone, dextroamphetamine, clomethiazole, bromocriptine, desipramine, nalmefene, naltrexone, disulfiram, acamprosate, topiramate, modafinil, nocaine, vanoxerine, bupropion, mecamylamine, varenicline, lamotrigine, gabapentin, rimonabant, iobgaine, 18- methoxycoronaridine and memantine.
  • drugs such as methadone, dextroamphetamine, clomethiazole, bromocriptine, desipramine, nalmefene, naltrexone, disulfiram, acamprosate, topiramate, modafinil, nocaine, vanoxerine, bupropion, mecamylamine, va
  • Erectile dysfunction currently affects more than 18 million men in the U.S., with 35-50% of men having diabetes experiencing it. In diabetics, there is higher glucose in the blood, and this leads to hyperglycemia-induced increased glycosylation of eNOS, rendering it inactive by reciprocally decreasing phosphorylation at Ser-1177. This leads to less nitric oxide production, one of the main physiologic causes of ED.
  • Current drugs on the market for ED are phosphodiesterase inhibitors, such as Viagra®. These drugs prevent degradation of cGMP, the moleculre responsible for activating the kinase called PKG. Activation of penile PKG leads to relaxation of smooth muscles during sexual stimulation thereby increasing blood flow. However, these drugs cannot be taken more than once a day and have side- effects associated with them. Other treatments for ED have their own limitations. Research on drugs for treating ED is expanding rapidly, and improved treatments are needed.
  • a method of inhibiting a subject's response to an addictive substance comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • the subject may be a non- human mammal, such as a mouse, a rat, or a primate, or may be a human.
  • Administering may comprise oral administration, intravenous administration, transdermal administration, or inhalation.
  • the addictive substance may be alcohol, a narcotic, such as
  • the subject may have been diagnosed with addictive behavior.
  • the subject may currently be using an addictive substance or not currently using an addictive substance.
  • the subject may further be receiving a second anti-addiction treatment.
  • a method of treating a subject for addiction comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • a method of method of reducing a subject's dependence on an addictive substance comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • a method of reducing a subject's chance of developing dependence on an addictive substance comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • a method of modifying a subject's response to drug acting through the dopamine receptor comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • An additional embodiment comprises a method of treating a subject with an addictive substance comprising (a) administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor; and (b) administering to said subject said addictive substance.
  • the subject may be is a non-human mammal, such as a a mouse, a rat, or a non-human primate.
  • the subject may instead be a human.
  • Administering may comprise oral administration, intravenous administration, transdermal administration, or inhalation.
  • the addictive substance may be alcohol, a narcotic, such as heroin or morphine, or a stimulant, such as amphetamine, 3,4-methylenedioxymethamphetamine, cocaine or methamphetamine.
  • Yet another embodiment comprises a method of treating erectile dysfunction (ED) in a male subject comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • the subject may be a mouse, a rat, or a non-human primate.
  • the subject may be a human. More than one GLP-1 receptor agonist, GLP-1 and/or GLP-1 analog may be administered.
  • Administering may comprises oral administration, intravenous administration, transdermal administration, or inhalation.
  • the subject may have diabetes and/or cardiovascular disease.
  • the method may further comprise administering to said subject a second ED therapy.
  • Still yet another embodiment includes a method of improving sexual performance in a male subject comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • the subject may be a mouse, a rat, or a non-human primate.
  • the subject may be a human. More than one GLP-1 receptor agonist, GLP-1 and/or GLP-1 analog may be administered.
  • Administering may comprises oral administration, intravenous administration, transdermal administration, or inhalation.
  • an additional embodiment comprises a method of reducing one or more symptoms of erectile dysfunction (ED) in a male subject comprising administering to said subject GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • the one or more symptoms may comprise partial erection, lack of erection, or limited erection duration.
  • More than one GLP-1 receptor agonist may be administered, including GLP-1 and GLP-1 analog or multiple GLP-1 analogs.
  • the administering may comprise oral administration, intravenous administration, transdermal administration, or inhalation.
  • a further embodiment includes a method of reducing one or more erectile dysfunction (ED) treatment side effects in a male subject comprising administering to said subject a reduced amount of ED treatment in combination with a GLP-1 or analog thereof or an agonist of GLP-1 receptor.
  • the one or more treatment side effects may comprise priapism, vision abnormalities, hearing loss, headache, muscle ache, and dyspepsia.
  • More, than one GLP-1 receptor agonist may be administered, including GLP-1 a GLP-1 analog, or multiple GLP-1 analogs.
  • the administering may comprise oral administration, intravenous administration, transdermal administration, or inhalation.
  • Also provide is a method treating diabetes and erectile dysfunction (ED) in a male subject comprising administering to said subject an amount of a GLP-1 R agonist effective to treat both diabetes and ED. More than one GLP-1 receptor agonist may be administered.
  • the GLP-1 receptor agonist may be a GLP-1 analog.
  • Administering may comprise oral administration, intravenous administration, transdermal administration, or inhalation.
  • the method may further comprise administering to said subject a diabetes therapy.
  • another may mean at least a second or more.
  • FIG. 1 An example of GLP-1 -induced increase in dopamine transporter surface expression. Representative immunoblots for surface and total fractions of dopamine transporter, tyrosine hydroxylase , and Na+/K+ ATPase.
  • FIG. 2 Freshly homogenized rat tissue. Lanes left to right are lung, penis, stomach and pancreas. Bands show a Western blot for GLP- 1 R.
  • FIGS. 4A-B Penile Sections.
  • FIGS. 4A-B Penile Sections.
  • GLP-1 glucagon-like peptide 1
  • DAT dopamine transporter
  • GLP-1 glucagon-like peptide 1
  • DAT dopamine transporter
  • GLP-1 regulates the cell surface levels of DAT in brain striatum
  • GLP-1 modulates the release of DA induced by amphetamine from striatal brain slices
  • GLP-1 regulates dopamine transporter function an assay of dopamine clearance.
  • exendin-4 a GLP-1 receptor agonist
  • ADHD is one of the most costly health conditions in the U.S. with annual cost of $77 billion. ADHD is diagnosed in approximately 3%-5% of the school-age population. About 30%-80% of children with the disorder will continue to have ADHD symptoms into adolescence. Studies point to disruption of the dopamine system as underlying ADHD. Consistent with the ability of GLP-1 to increase dopamine transporter cell surface expression and to blunt locomotion, these data implicate GLP-1 has a putative therapeutic agent for ADHD. The results further have therapeutic implications for both diabetes and obesity, which affect 2 in 3 adults in the United States.
  • GLP-1 receptor GLP-1 receptor
  • the inventors have demonstrated, for the first time, the presence of the GLP-IR in the penis, thereby opening the possibility of using GLP-1 as an ED therapy. This was demonstrated by both Western blotting (FIG. 2) and immunohistochemistry coupled with confocal microscopy (FIGS. 3 and 4A-B).
  • DAT Dopamine Transporter
  • the dopamine transporter is a member of the subfamily of monoamine transporters with numerous common topological structures and significant amino acid sequence homology. DAT has been identified as located on the distal end of chromosome 5 (5pl5.3) (Giros et al., 1992). Kawarai et al. (1997), isolated and characterized the human DAT gene (hDAT) including about 1 kb of 5 '-flanking region. The hDAT gene spans over 64 kb, consisting of 15 exons separated by 14 introns. The intron-exon structure of the hDAT gene is most similar to that of the human NET gene.
  • Promoter sequence analysis demonstrated a 'TATA'-less, 'CAT'-less and G+C-rich structure. Two E box and several Sp-1 -binding sites exist in the promoter region. These structural features are similar to that of the human D1A dopamine receptor gene and the human monoamine oxidase A gene.
  • the DAT gene encodes for a 620-amino acid protein with a calculated molecular weight of 68,517 (Giros et al., 1992) and is associated with numerous neuropsychiatric disorders (Bannon, 2001). Examples of neurological diseases involving dopamine transporter function include schizophrenia, addiction disorders, attention deficit hyperactivity disorder (ADHD), psychoses, Tourette's syndrome, and Parkinson's disease.
  • ADHD attention deficit hyperactivity disorder
  • Parkinson's disease Parkinson's disease.
  • an addiction is a chronic neurobiological disorder that has genetic, psychosocial, and environmental dimensions and is characterized by one of the following: the continued use of a substance despite its detrimental effects, impaired control over the use of a substance (compulsive behavior), and preoccupation with a substance use for non-therapeutic purposes ( .£?., craving the drug).
  • Tolerance to a drug and physical dependence are not defining characteristics of addiction, although they typically accompany addiction to certain drugs.
  • Tolerance is a pharmacologic phenomenon where the dose of a medication needs to be continually increased in order to maintain its desired effects. For instance, individuals with severe chronic pain taking opiate medications (like morphine) will need to continually increase the dose in order to maintain the drug's analgesic (pain-relieving) effects.
  • Physical dependence is also a pharmacologic property and means that if a certain drug is abruptly discontinued, an individual will experience certain characteristic withdrawal signs and symptoms. Many drugs used for therapeutic purposes produce withdrawal symptoms when abruptly stopped, for instance oral steroids, certain antidepressants, benzodiazepines, and opiates.
  • Addiction is now narrowly defined as "uncontrolled, compulsive use”; if there is no harm being suffered by, or damage done to, the patient or another party, then clinically it may be considered compulsive, but to the definition of some it is not categorized as 'addiction.' In practice, the two kinds of addiction are not always easy to distinguish. Addictions often have both physical and psychological components.
  • the speed with which a given individual becomes addicted to various substances varies with the substance, the frequency of use, the means of ingestion, the intensity of pleasure or euphoria, and the individual's genetic and psychological susceptibility.
  • Opioid dependent individuals have different responses to even low doses of opioids than the majority of people, although this may be due to a variety of other factors, as opioid use heavily stimulates pleasure-inducing neurotransmitters in the brain. Nonetheless, because of these variations, in addition to the adoption and twin studies that have been well replicated, much of the medical community is satisfied that addiction is in part genetically moderated. That is, one's genetic makeup may regulate how susceptible one is to a substance and how easily one may become psychologically attached to a pleasurable routine.
  • the DSM definition of addiction can be boiled down to compulsive use of a substance (or engagement in an activity) despite ongoing negative consequences - this is also a summary of what used to be called "psychological dependency.”
  • Physical dependence on the other hand, is simply needing a substance to function. Humans are all physically dependent on oxygen, food and water. A drug can cause physical dependence and not addiction (for example, some blood pressure medications, which can produce fatal withdrawal symptoms if not tapered) and can cause addiction without physical dependence (the withdrawal symptoms associated with cocaine are all psychological, there is no associated vomiting or diarrhea as there is with opioid withdrawal).
  • Addiction can in theory be derived from any rewarding behaviour, and is believed to be strongly associated with the dopaminergic system of the brain's reward system (as in the case of cocaine and amphetamines).
  • a person who is physically dependent, but not psychologically dependent can have their dose slowly dropped until they are no longer physically dependent. However, if that person is psychologically dependent, they are still at serious risk for relapse into abuse and subsequent physical dependence.
  • Psychological dependence does not have to be limited only to substances; even activities and behavioural patterns can be considered addictions, if they become uncontrollable, e.g., problem gambling, Internet addiction, computer addiction, sexual addiction/pornography addiction, overeating, self-injury, compulsive buying, or work addiction.
  • Some medical systems including those of at least 15 states of the United States, refer to an Addiction Severity Index to assess the severity of problems related to substance use.
  • the index assesses problems in six areas: medical, employment/support, alcohol and other drug use, legal, family/social, and psychiatric.
  • Treatments usually involve planning for specific ways to avoid the addictive stimulus, and therapeutic interventions intended to help a client learn healthier ways to find satisfaction.
  • Clinical leaders in recent years have attempted to tailor intervention approaches to specific influences that affect addictive behavior, using therapeutic interviews in an effort to discover factors that led a person to embrace unhealthy, addictive sources of pleasure or relief from pain.
  • Alcohol dependence is acknowledged by the American Medical Association as a disease because it has a characteristic set of signs and symptoms and a progressive course. It has significant socio-economic impact and remains a challenge to treat.
  • Opioid dependence is a medical diagnosis characterized by an individual's inability to stop using opioids even when objectively it is in his or her best interest to do so.
  • the WHO introduced "dependence" as a cluster of physiological, behavioral and cognitive phenomena of variable intensity, in which the use of drug (or drugs) takes on a high priority. The necessary descriptive characteristics are preoccupation with a desire to obtain and take the drug and persistent drug-seeking behavior.
  • Opiates include the natural opiates (alkaloids contained in the resin of the opium poppy, primarily morphine, codeine, and thebaine; also, the leaves from Mitragyna Speciosa (also known as Kratom), and Salvinorin A).
  • Semisynthetic opioids include those created from natural opiates, such as hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmo hine (heroin), nicomorphine, dipropanoylmorphine, benzylmorphine and ethylmorphine and buprenorphine.
  • Fully synthetic opioids include fentanyl, pethidine, methadone, tramadol and dextropropoxyphene.
  • Endogenous opioid peptides include endorphins, enkephalins, dynorphins, and endomorphins.
  • Amphetamine dependence refers to a state of dependence on a drug in the amphetamine class. Tolerance is developed rapidly in amphetamine abuse, thereby the amount of the drug that is needed to satisfy the addiction needs to be increased at regular intervals. Many users will repeat the amphetamine cycle by taking more of the drug during the withdrawal. This leads to a very dangerous cycle and may involve the use of other drugs to get over the withdrawal process. Users will commonly stay up for 2 or 3 days to avoid the withdrawals then dose themselves with benzodiazepines, barbiturate, and in some cases heroin, to help them stay calm while they recuperate or simply to extend the positive effects of the drug. Chronic abusers of amphetamine often insufflate, smoke or inject the drug in order to experience a rush, with extra risks for infection, vein damage and overdose.
  • Amphetamine is a chiral compound.
  • the racemic mixture can be divided into its optical isomers: levo- and dextro-amphetamine.
  • Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, from empathogens, MDA (3,4-Methylenedioxyamphetamine) and MDMA (3,4-Methylenedioxy- N-methamphetamine) known as ecstasy, to the N-methylated form, methamphetamine known as "meth,” and to decongestants such as ephedrine (EPH).
  • Amphetamine is a homologue of phenethylamine.
  • Sedatives, hypnotics, or anxiolytics are drugs of the psychoactive class whose primary function is to induce sleep and to be used in the treatment of insomnia and in surgical anesthesia.
  • "sleep" is metaphorical and there are no regular sleep stages or cyclical natural states when used in anesthesia; patients rarely recover from anesthesia feeling refreshed and with renewed energy.
  • drugs in this class generally produce dose- dependent effects, ranging from anxiolysis to production of unconsciousness, they are often referred to collectively as sedative-hypnotic drugs.
  • Hypnotic drugs are regularly prescribed for insomnia and other sleep disorders, with over 95% of insomnia patients being prescribed hypnotics in some countries. However, many hypnotic drugs are habit-forming. Hypnotic medication when prescribed should be used for the shortest period of time possible. In addition, the benzodiazepine and nonbenzodiazepine hypnotic medications also have a number of side effects such as daytime fatigue, motor vehicle crashes, cognitive impairments and falls and f actures. Gradual discontinuation of hypnotics leads to improved health without worsening of sleep. Preferably they should be prescribed for only a few days at the lowest effective dose and avoided altogether wherever possible in the elderly.
  • Treatment for drug abuse or dependence begins with recognizing the problem.
  • Treatment of drug dependency involves stopping drug use either gradually or abruptly (detoxification), support, and staying drug free (abstinence). People with acute intoxication or drug overdose may need emergency treatment. Sometimes, the person loses consciousness and might need to be on a breathing machine (mechanical respirator) temporarily. The treatment depends on the drug being used.
  • Detoxification is the withdrawal of an abused substance in a controlled environment. Sometimes a drug with a similar action is taken instead, to reduce the side effects and risks of withdrawal. Detoxification can be done on an inpatient or outpatient basis. Palliative treatments may ease the discomfort of withdrawal.
  • Erectile dysfunction is a sexual dysfunction characterized by the inability to develop or maintain an erection of the penis sufficient for satisfactory sexual performance.
  • An erection occurs as a hydraulic effect due to blood entering and being retained in sponge-like bodies within the penis. The process is most often initiated as a result of sexual arousal, when signals are transmitted from the brain to nerves in the penis.
  • Penile erection is managed by two different mechanisms. The first one is the reflex erection, which is achieved by directly touching the penile shaft. The second is the psychogenic erection, which is achieved by erotic or emotional stimuli. The former uses the peripheral nerves and the lower parts of the spinal cord, whereas the latter uses the limbic system of the brain. In both conditions, an intact neural system is required for a successful and complete erection. Stimulation of penile shaft by the nervous system leads to the secretion of nitric oxide (NO), which causes the relaxation of smooth muscles of corpora cavernosa (the main erectile tissue of penis), and subsequently penile erection. Additionally, adequate levels of testosterone (produced by the testes) and an intact pituitary gland are required for the development of a healthy erectile system.
  • NO nitric oxide
  • impotence may develop due to hormonal deficiency, disorders of the neural system, lack of adequate penile blood supply or psychological problems. Restriction of blood flow can arise from impaired endothelial function due to the usual causes associated with coronary artery disease, but can also be caused by prolonged exposure to bright light.
  • Erectile dysfunction is indicated when an erection is difficult to produce.
  • the most important organic causes are cardiovascular disease and diabetes, neurological problems (spinal cord and brain injuries, nerve disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, and stroke, trauma from prostatectomy surgery), hormonal insufficiencies (hypogonadism), kidney failure, aging and drug side effects (such as anti-depressants and nicotine).
  • Psychological impotence is where erection or penetration fails due to thoughts or feelings (psychological reasons) rather than physical impossibility; this is somewhat less frequent but often can be helped. Notably in psychological impotence, there is a strong response to placebo treatment. Erection, tied closely as it is about ideas of physical well being, can have severe psychological consequences.
  • the first line treatment of erectile dysfunction consists of a trial of PDE5 inhibitor drugs (the first of which was sildenafil or Viagra®).
  • treatment can involve prostaglandin tablets in the urethra, intracavemous injections with a fine needle into the penis that cause swelling, a penile prosthesis, a penis pump or vascular reconstructive surgery.
  • Surgical intervention for a number of different conditions may remove anatomical structures necessary to erection, damage nerves, or impair blood supply.
  • Complete removal of the prostate gland or external beam radiotherapy of the gland are common causes of impotence; both are treatments for prostate cancer.
  • a useful and simple way to distinguish between physiological and psychological impotence is to determine whether the patient ever has an erection. If never, the problem is likely to be physiological. If sometimes (however rarely), it could be physiological or psychological.
  • the current diagnostic and statistical manual of mental diseases includes duplex ultrasound, penile nerve function, nocturnal penile tumescence (NPT) testing, penile biothesiometry, dynamic infusion cavernosometry (DICC), corpus cavernosometry, digital subtraction angiography (DSA), and magnetic resonance angiography (MRA).
  • Testosterone supplements may be used for cases due to hormonal deficiency.
  • the cause is more usually lack of adequate penile blood supply as a result of damage to inner walls of blood vessels. This damage is more frequent in older men, and often associated with disease, in particular diabetes.
  • Treatments work on a temporary basis: they enable an erection to be attained and maintained long enough for intercourse, but do not permanently improve the underlying condition.
  • ED can in many cases be treated by drugs taken orally, injected, or as penile suppositories.
  • drugs increase the efficacy of nitric oxide, which dilates the blood vessels of corpora cavernosa.
  • Exercise particularly aerobic exercise is an effective cheap treatment for erectile dysfunction.
  • Another non-pharmacologic method involves a purpose-designed external vacuum pump can be used to attain erection, with a separate compression ring fitted to the penis to maintain it. More drastically, inflatable or rigid penile implants may be fitted surgically. All these mechanical methods are based on simple principles of hydraulics and mechanics and are quite reliable, but have their disadvantages. Intracavemous pharmacotherapy is also used by men with certain medical conditions such as hypertension or high blood pressure.
  • the cyclic nucleotide phosphodiesterases constitute a group of enzymes that catalyse the hydrolysis of the cyclic nucleotides cyclic AMP and cyclic GMP. They exist in different molecular forms and are unevenly distributed throughout the body.
  • PDE5 One of the forms of phosphodiesterase is termed PDE5.
  • the prescription PDE5 inhibitors sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) are prescription drugs which are taken orally. They work by blocking the action of PDE5, which causes cGMP to degrade.
  • Alprostadil has become available in some countries as a topical cream (under the brand name Befar®), and preliminary studies have shown a clinical efficacy of up to 83%.
  • the present invention provides new methods for treating drug dependence/addiction.
  • Subjects suffering from dependence/addiction include individuals addicted to a variety of agents, such as narcotics and amphetamines. They addition may also be a compulsion, such as some version of obsessive-compulsive disorder (excessive cleanliness, hoarding, overeating etc.).
  • a GLP-1R modulator will be selected based on the particular conditions of the patient, including but not limited a consideration of other drugs that the patient may be taking.
  • the present invention also provides new methods for treating ED.
  • Subjects suffering from ED include a variety of individuals, ranging from those having cardiovascular disease and diabetes, neurological problems, hormonal insufficiencies, kidney failure, aging and drug side effects.
  • a GLP-1R modulator will be selected based on the particular conditions of the patient, including but not limited a consideration of other drugs that the patient may be taking. 1.
  • GLP-1 Glucagon-like peptide- 1
  • the major source of GLP-1 in the periphery is the intestinal L cell that secretes GLP-1 as a gut hormone.
  • the biologically active forms of GLP-1 are: GLP-l-(7-37) and GLP-1 -(7-36)-NH 2 .
  • GLP-1 is also a neurotransmitter synthesized by a small population of neurons in the nucleus of the solitary tract (NTS) in the caudal brainstem. These neurons project widely into the brain and putatively release GLP-1.
  • NTS nucleus of the solitary tract
  • the GLP-1R is expressed throughout the brain and the relative contributions of central (brain) and peripheral both GLP-1 peptide sources and receptor signaling are unresolved.
  • GLP-1 secretion by L cells is dependent on the presence of nutrients in the lumen of the small intestine.
  • the secretagogues (agents that cause or stimulate secretion) of this hormone include major nutrients like carbohydrate, protein and lipid.
  • GLP-1 Once in the circulation, GLP-1 has a half life of less than 2 minutes, due to rapid degradation by the enzyme dipeptidyl peptidase-4.
  • GLP-1 possesses several physiological properties that make it (and its analogs) a subject of intensive investigation as a potential treatment of diabetes mellitus.
  • the known physiological functions of GLP-1 include (a) increasing insulin secretion from the pancreas in a glucose-dependent manner; (b) decreasing glucagon secretion from the pancreas; (c) increasing ⁇ cell mass and insulin gene expression; (d) inhibiting acid secretion and gastric emptying in the stomach; (e) decreasing food intake by increasing satiety; and (f) promoting insulin sensitivity
  • Glucagon-like peptide- 1 analogs are a new class of drug for treatment of type 2 diabetes.
  • One of their advantages is that they have a lower risk of causing hypoglycemia.
  • Exenatide (2005) and liraglutide (2010) are approved, and albiglutide and taspoglutide remain under evaluation.
  • Exenatide Marketed as Byetta®, exenatide is approved for the treatment of diabetes mellitus type 2. Exenatide is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, 30 to 60 minutes before the first and last meal of the day. Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster. It displays biological properties similar to human glucagon-like peptide- 1 (GLP-1), a regulator of glucose metabolism and insulin secretion. According to the package insert, exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying, although the mechanism of action is still under study.
  • GLP-1 human glucagon-like peptide- 1
  • Exenatide is a 39-amino-acid peptide that is an insulin secretagogue with glucoregulatory effects. Exenatide was approved by the FDA in 2005 for patients whose diabetes was not well-controlled on other oral medication. The medication is injected subcutaneously twice per day using a pre-filled pen device. The abdomen is a common injection site, after the area is cleaned with an alcohol pad. A new pen must first be tested to see if the medicine is flowing
  • GLP-1 and GIP glucose-dependent insulinotropic peptide
  • GLP-1 and GIP stimulate insulin secretion from the ⁇ cells of the islets of Langerhans in the pancreas.
  • GLP-1 causes insulin secretion in the diabetic state; however; GLP-1 itself is ineffective as a clinical treatment for diabetes as it has a very short half-life in vivo.
  • Exenatide bears a 50% amino acid homology to GLP-1 and it has a longer half-life in vivo. Thus, it was tested for its ability to stimulate insulin secretion and lower blood glucose in mammals and was found to be effective in the diabetic state. In studies on rodents it has also been shown to increase the number of beta cells in the pancreas.
  • Exenatide is approved "as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a biguanide, or a combination of metformin and a sulfonylurea but have not achieved adequate glycemic control.” It has now been approved for use with thiazolidinediones such as pioglitazone or rosiglitazone.
  • Exenatide raises insulin levels quickly (within about ten minutes of administration) with the insulin levels subsiding substantially over the next hour or two.
  • a dose taken after meals has a much smaller effect on blood sugar than one taken beforehand.
  • the effects on blood sugar diminish after 6-8 hours.
  • the medicine is available in two doses: 5 meg and 10 meg. Treatment often begins with the 5 meg dosage, which is increased if adverse effects are not significant.
  • Exenatide (Byetta®) autoinjector must be stored in a refrigerator between 36°F (2°C) and 46°F (8°C) before first use, and then at a temperature between 36°F (2°C) and 77°F (25°C). In hot weather, therefore, they should be refrigerated. Exenatide (Byetta®) pens contain sixty doses designed to be used twice a day for 30 days.
  • Exenatide is believed to facilitate glucose control in at least five ways. Exenatide augments pancreas response (i.e., increases insulin secretion) in response to eating meals; exenatide suppresses pancreatic release of glucagon in response to eating, which helps stop the liver from overproducing sugar when it is unneeded, which prevents hyperglycemia (high blood sugar levels); exenatide helps slow down gastric emptying and thus decreases the rate at which meal-derived glucose appears in the bloodstream; exenatide has a subtle yet prolonged effect to reduce appetite, promote satiety via hypothalamic receptors (different receptors than for amylin); and exenatide reduces liver fat content.
  • pancreas response i.e., increases insulin secretion
  • exenatide suppresses pancreatic release of glucagon in response to eating, which helps stop the liver from overproducing sugar when it is unneeded, which prevents hyperglycemia (high blood sugar levels)
  • exenatide helps slow down gastric
  • exenatide used are gastrointestinal in nature, including acid or sour stomach, belching, diarrhea, heartburn, indigestion, nausea, and vomiting; exenatide is therefore not meant for people with severe gastrointestinal disease.
  • Other side effects include dizziness, headache, and feeling jittery.
  • Drug interactions listed on the package insert include delayed or reduced concentrations of Lovastatin, Paracetamol (Acetaminophen), and Digoxin, although this has not been proven to alter the effectiveness of these other medications.
  • Liraglutide marketed under the brand name Victoza®, is a long-acting glucagon-like peptide- 1 (GLP-1) analog that has been developed for the treatment of type 2 diabetes.
  • the product was approved by the European Medicines Agency (EMEA) in 2009, and by the U.S. Food and Drug Administration (FDA) in 2010.
  • EMEA European Medicines Agency
  • FDA U.S. Food and Drug Administration
  • Liraglutide improves control of blood glucose. It reduces meal- related hyperglycemia (for 12 hours after administration) by increasing insulin secretion, delaying gastric emptying, and suppressing prandial glucagon secretion.
  • Liraglutide may have advantages over current therapies: (a) it acts in a glucose-dependent manner, meaning that it will stimulate insulin secretion only when blood glucose levels are higher than normal, and consequently, it shows negligible risk of hypoglycemia; (b) it has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies); (c) it decreases appetite and maintains body weight, as shown in a head-to-head study versus glimepiride; (d) it lowers blood triglyceride levels; and (e) it has only mild and transient side effects, mainly gastrointestinal.
  • Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetes.
  • GLP-1 in its natural form, is short-lived in the body (the half-life after subcutaneous injection is approximately one hour), so it is not very useful as a therapeutic agent.
  • liraglutide has a half-life after subcutaneous injection of 11-15 hours, making it suitable for once-daily dosing (which is less frequent than the currently approved Byetta form of exenatide which is twice daily, but is considerably more frequent than the once weekly form of exenatide that is scheduled for a decision from the FDA regarding marketing approval by early March 2010 ).
  • the prolonged action of liraglutide is achieved by attaching a fatty acid molecule at one position of the GLP-1 molecule, enabling it to bind to albumin within the subcutaneous tissue and bloodstream.
  • the active GLP-1 is then released from albumin at a slow, consistent rate. Binding with albumin also results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-1.
  • Sitagliptin (trade name Januvia®) is an oral antihyperglycemic (anti- diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, Sitagliptin being the only second generation DPP-4 inhibitor currently available in the USA.
  • This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2.
  • the benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values.
  • Exenatide (Byetta®) also works by its effect on the incretin system.
  • the DPP-4 enzyme is known to be involved in the suppression of certain malignancies, particularly in limiting the tissue invasion of these tumours. Inhibiting the DPP-4 enzymes may allow some cancers to progress.
  • a study of DPP-4 inhibition in human non-small cell lung cancer (NSCLC) concluded that "DPPIV functions as a tumor suppressor, and its downregulation may contribute to the loss of growth control in NSCLC cells.”
  • the risk of cancer suppression with DPP-4 down-regulation applies to all the DPP-4 inhibitors on the market in addition to sitagliptin (saxagliptin and vildagliptin)
  • Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4).
  • DPP-4 dipeptidyl peptidase 4
  • This enzyme breaks down the incretins GLP-1 and GIP, gastrointestinal hormones that are released in response to a meal.
  • GLP-1 and GEP inactivation GLP-1 and GIP are able to potentiate the secretion of insulin and suppress the release of glucagon by the pancreas.
  • compositions in a form appropriate for the intended application. Generally, this will entail preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.
  • compositions of the present invention comprise an effective amount of the substance to cells, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Such compositions also are referred to as inocula.
  • pharmaceutically or pharmacologically acceptable refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
  • compositions of the present invention may include classic pharmaceutical preparations. Administration of these compositions according to the present invention will be via any common route so long as the target tissue is available via that route. Such routes include oral, nasal, buccal, rectal, vaginal or topical route. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, or intravenous injection. Such compositions would normally be administered as pharmaceutically acceptable compositions, described supra.
  • the active compounds may also be administered parenterally or intraperitoneally.
  • Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • a coating such as lecithin
  • surfactants for example, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sulfate, sodium sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • compositions of the present invention may be formulated in a neutral or salt form.
  • Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethyl
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like.
  • the solution For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences," 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards. 4.
  • the compounds of the present invention are provided in combination with a second agent or therapy - either an anti-addictive substance/therapy or an agent designed to eliminate to reduce addiction, or to treat ED.
  • a second agent or therapy either an anti-addictive substance/therapy or an agent designed to eliminate to reduce addiction, or to treat ED.
  • These therapies may be provided together, i.e., administering both agents/therapies at the same time. This may be achieved by administering a single composition or pharmacological formulation that includes both agents, or by administering two distinct compositions or formulations, at the same time, wherein one composition includes the GLP-1 agonist and the other includes the second agent.
  • the GLP-1 treatment may precede or follow the second agent by intervals ranging from minutes to weeks.
  • the second agent and the GLP-1 treatment are made separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the GLP-1 therapy would still be able to exert an advantageous effect on the subject.
  • a second agent/therapy for treating addiction includes counseling, an palliative agent or therapy or a addictive agent substitute, such a methadone.
  • a second agent for ED therapy includes inhibitors of cyclic nucleotide phosphodiesterases (PDEs), which constitute a group of enzymes that catalyse the hydrolysis of the cyclic nucleotides cyclic AMP and cyclic GMP.
  • PDE5 inhibitors sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) are prescription drugs which are taken orally. They work by blocking the action of PDE5, which causes cGMP to degrade.
  • Alprostadil has become available in some countries as a topical cream (under the brand name Befar®), and preliminary studies have shown a clinical efficacy of up to 83%.
  • GLP-1 100 nM was shown to increase DAT cell surface expression in rat striatal slices. Striatal slices were exposed to either vehicle or GLP-1 for 20 min and level of DAT surface expression was evaluated using Western Blot of biotinylated brain tissue. GLP-1 treatment significantly increased surface expression of DAT, quantified as the ratio of surface to total DAT. GLP-1 did not affect surface expression of the Na+/K+ ATPase (Fig. 4B) suggesting that GLP-1 regulation of DAT surface levels is not due to a global effect on trafficking of plasma membrane proteins. In addition, the absence of tyrosine hydroxylase (TH, a cytosolic protein found in DAT terminals) from the biotinylated surface fraction serves a control for the integrity of our slice preparation and specificity of the surface signal.
  • TH tyrosine hydroxylase
  • AMPH-induced DA efflux was used to evaluate AMPH-induced DA efflux in striatal slices.
  • AMPH (10 ⁇ ) was perfused onto the slices after pretreatment with either vehicle or GLP-1 (100 nM, for 20 min).
  • Pretreatment with GLP-1 significantly potentiates the AMPH-induced increase in extracellular DA.
  • This AMPH-induced increase in extracellular DA was cocaine sensitive suggesting it is mediated by DAT.
  • Exenatide is supplied for SC injection as a sterile, preserved isotonic solution in a glass cartridge that has been assembled in a pen-injector (pen).
  • pen pen-injector
  • Each milliliter (mL) contains 250 micrograms (meg) synthetic exenatide, 2.2 mg metacresol as an antimicrobial preservative, mannitol as a tonicity-adjusting agent, and glacial acetic acid and sodium acetate trihydrate in water for injection as a buffering solution at pH 4.5.
  • Two prefilled pens are available to deliver unit doses of 5 meg or 10 meg. Each prefilled pen will deliver 60 doses to provide for 30 days of twice daily administration (BID).
  • GLP-1 and/or GLP-1 analogs to decrease the dependency on such drugs and to decrease the behaviors induced by these drugs.
  • GLP-1 and/or GLP-1 analogs An individual previously addicted to amphetamine-like substances such as methamphetamine and/or drug of abuse acting on the dopaminergic system including cocaine will be administered GLP-1 and/or GLP-1 analogs to decrease the probability of relapse.
  • rat tissue was ground up on dry ice and homogenized in lysis buffer containing SDS, separated by SDS-PAGE and the blot probed for GLP-1 R with an antibody to it (GLP-1R (H-55): sc-66911, Santa Cruz Biotechnologies). Lung, stomach and pancreas were used as positive controls.
  • GLP-1R H-55
  • sc-66911 Santa Cruz Biotechnologies
  • FIGS. 3 and 4A-B the inventors sought to establish more specifically the localization of the GLP-1 receptor in the penile tissue. They performed both 40 micron longitudinal and transverse sections of the paraformaldehyde-perfused rat penis and stained for both GLP-1 receptor (green fluoresence) and nNOS (neuronal nitric oxide synthase) (red fluoresence). In FIG. 3, in the longitudinal section, the inventors observed abundant neuronal staining of the GLP-1 receptor in the corpora cavernosa.
  • FIG. 4A also shows a longitudinal section, with GLP-1 receptor colocalazing with nNOS in the nerves (yellow).
  • FIG. 4B shows a transverse section of the penis, where the GLP-1 receptor is in endothelial cells.
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure, while the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. F. References

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur l'utilisation du GLP-1 et de ses analogues ou des agonistes du récepteur du GLP-1 pour moduler la signalisation du transporteur de la dopamine. Les implications de cette capacité comprennent l'utilisation du GLP-1 et de ses analogues ou des agonistes du récepteur du GLP-1, tels que l'exendine-4, pour tempérer la réaction comportementale à des drogues toxicomanogènes, pour diminuer la toxicomanie, pour empêcher la récidive à l'abus de drogue et pour traiter les troubles du cerveau, tels que les troubles neuropsychiatriques, comprenant le trouble d'hyperactivité avec déficit de l'attention (THADA). La présente invention porte également sur l'utilisation du GLP-1 et de ses analogues ou des agonistes du récepteur du GLP-1 pour activer le GLP-1 R dans le tissu du pénis, tel que pour le traitement du dysfonctionnement érectile soit en tant que monothérapie, soit en combinaison avec d'autres traitements, tels que les inhibiteurs du PDE5.
PCT/US2011/040008 2010-06-24 2011-06-10 Modulation par le récepteur du glp-1 de la pharmacodépendance, des troubles neuropsychiatriques et du dysfonctionnement érectile WO2011162989A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35825110P 2010-06-24 2010-06-24
US61/358,251 2010-06-24

Publications (2)

Publication Number Publication Date
WO2011162989A2 true WO2011162989A2 (fr) 2011-12-29
WO2011162989A3 WO2011162989A3 (fr) 2012-03-08

Family

ID=44534602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040008 WO2011162989A2 (fr) 2010-06-24 2011-06-10 Modulation par le récepteur du glp-1 de la pharmacodépendance, des troubles neuropsychiatriques et du dysfonctionnement érectile

Country Status (2)

Country Link
US (1) US20120021979A1 (fr)
WO (1) WO2011162989A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083826A3 (fr) * 2011-12-09 2013-08-01 Novo Nordisk A/S Agonistes du glp-1

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120282255A1 (en) * 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
JP7526716B2 (ja) 2018-03-23 2024-08-01 カーモット セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体の調節剤
WO2020112253A2 (fr) * 2018-10-16 2020-06-04 The Board Of Regents Of The University Of Oklahoma Utilisations d'agonistes du récepteur du peptide-1 de type glucagon pour le traitement de la perte auditive induite par un traumatisme
MD4097099T2 (ro) 2020-02-07 2025-02-28 Gasherbrum Bio Inc Agonişti GKP-1 heterociclici
EP4461355A3 (fr) 2021-05-03 2025-01-15 Carmot Therapeutics, Inc. Agonistes du récepteur glp-1 de la benzimidazoyle, compositions pharmaceutiques les comprenant et leurs procédés d'utilisation
MX2023013492A (es) 2021-05-13 2024-02-29 Carmot Therapeutics Inc Moduladores de los receptores acoplados a proteinas g.
EP4490155A1 (fr) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
EP4496797A1 (fr) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. Dérivés de 5,8-dihydro-1,7-naphtyridine utiles en tant qu'agonistes de glp-1 pour le traitement du diabète
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2024026338A1 (fr) 2022-07-27 2024-02-01 Carmot Therapeutics, Inc. Agonistes du récepteur rcpg n-hétérocylique, compositions pharmaceutiques les comprenant et leurs procédés d'utilisation
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
WO2024131869A1 (fr) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Agonistes hétérocycliques du glp-1
WO2024138048A1 (fr) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Agonistes de glp-1 hétérocycliques
WO2024169952A1 (fr) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
TW202506102A (zh) 2023-06-30 2025-02-16 美商迦舒布魯姆生物有限公司 雜環的glp-1促效劑
WO2025015269A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Composés, compositions et procédés
WO2025015268A1 (fr) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulateurs de l'activité du récepteur de la calcitonine et/ou du récepteur de l'amyline
WO2025045208A1 (fr) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Agonistes de glp-1 à base de hétéroaryl-hétérocycloalkyl

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061434A2 (fr) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. Formulation pharmaceutique de glp-1 et son utilisation pour traiter un syndrome metabolique
WO2007146448A1 (fr) * 2006-06-07 2007-12-21 Nastech Pharmaceutical Company Inc. Formulations pharmaceutiques de dérivés glp-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANNON, EUR. NEUROPSYCHOPHARMACOL., vol. 11, no. 6, 2001, pages 449 - 55
GIROS ET AL., MOL. PHARMACOL., vol. 42, no. 3, 1992, pages 383 - 390
KAWARAI ET AL., GENE, AUG, vol. 11, no. 195, pages 1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013083826A3 (fr) * 2011-12-09 2013-08-01 Novo Nordisk A/S Agonistes du glp-1

Also Published As

Publication number Publication date
WO2011162989A3 (fr) 2012-03-08
US20120021979A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
US20120021979A1 (en) GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
Coulter et al. Centrally acting agents for obesity: past, present, and future
Lynch et al. Biological basis of sex differences in drug abuse: preclinical and clinical studies
Gold Opiate addiction and the locus coeruleus: the clinical utility of clonidine, naltrexone, methadone, and buprenorphine
Kleber Pharmacologic treatments for heroin and cocaine dependence
KR20030025902A (ko) 덱스트로메토르판 및 옥시다제 억제제의 환자의 마약 및항진정제의 중단을 위한 용도
US20030207943A1 (en) Treatment of disorders secondary to organic impairments
Jeong et al. Anti-obesity weight loss medications: Short-term and long-term use
Koob et al. Opioids
RU2322985C2 (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
CA2444269C (fr) Traitement de troubles secondaires provoques par des deficiences organiques
WO2015153263A1 (fr) Compositions et procédés pour traiter la dépendance
Welch et al. Opiate antagonists for the treatment of schizophrenia
Shaefer Jr Lixisenatide: a new member of the Glucagon-Like peptide 1 receptor agonist class of incretin therapies
O’Brien Opioid addiction
Maremmani et al. Understanding the pathogenesis of drug addiction in order to implement a correct pharmacological intervention
Valsamakis et al. New molecular targets in the pathophysiology of obesity and available treatment options under investigation
CN112867730A (zh) 用于治疗高胰岛素低血糖症的阿维西特
Ginzburg et al. The role of naltrexone in the management of drug abuse
Hall et al. Rapid opiate detoxification treatment
Bailey Pharmacological treatments for substance use disorders
Crowe et al. Pharmacologically induced penile erection (PIPE) as a maintenance treatment for erectile impotence: a report of 41 cases
EP3765056B1 (fr) Compositions, méthodes et utilisations d'un peptide-1 associé à l'extrémité c-terminale de la téneurine (tcap-1) pour traiter la dépendance aux opioïdes
AU2005219422A2 (en) Use of enhanced water to improve blood sugar management
Smith Painful diabetic peripheral neuropathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11738856

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11738856

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载